华东医药：乌司奴单抗注射液调整至常规目录管理

Core Viewpoint - East China Pharmaceutical announced adjustments to its product management, impacting payment scope for certain drugs [1] Group 1: Product Management Changes - The company's wholly-owned subsidiary, Hangzhou Sino-American East China Pharmaceutical Co., Ltd., has adjusted the management of Ustinumab injection to routine directory management, resulting in changes to the payment scope compared to the previous version of the drug directory [1] - The company's cooperative products, Senaparib capsules and Pentanedioic acid linagliptin capsules, have been included in the negotiated drug list during the agreement period [1] - Zewokiorunsai injection has been included in the commercial insurance innovative drug directory [1]